1. Home
  2. AKBA vs RXST Comparison

AKBA vs RXST Comparison

Compare AKBA & RXST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Akebia Therapeutics Inc.

AKBA

Akebia Therapeutics Inc.

HOLD

Current Price

$1.43

Market Cap

375.0M

Sector

Health Care

ML Signal

HOLD

Logo RxSight Inc.

RXST

RxSight Inc.

HOLD

Current Price

$7.52

Market Cap

305.0M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
AKBA
RXST
Founded
2007
1997
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Electromedical & Electrotherapeutic Apparatus
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
375.0M
305.0M
IPO Year
2014
2021

Fundamental Metrics

Financial Performance
Metric
AKBA
RXST
Price
$1.43
$7.52
Analyst Decision
Strong Buy
Hold
Analyst Count
4
10
Target Price
$5.25
$9.78
AVG Volume (30 Days)
2.2M
775.8K
Earning Date
05-07-2026
05-06-2026
Dividend Yield
N/A
N/A
EPS Growth
93.94
N/A
EPS
N/A
N/A
Revenue
N/A
$134,479,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$10.06
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.14
$5.90
52 Week High
$4.08
$16.73

Technical Indicators

Market Signals
Indicator
AKBA
RXST
Relative Strength Index (RSI) 51.31 57.03
Support Level $1.30 $7.34
Resistance Level $1.55 $9.11
Average True Range (ATR) 0.08 0.43
MACD 0.00 0.16
Stochastic Oscillator 42.37 89.84

Price Performance

Historical Comparison
AKBA
RXST

About AKBA Akebia Therapeutics Inc.

Akebia Therapeutics Inc is a fully integrated biopharmaceutical company. The Company's operating segment is the business of developing and commercializing novel therapeutics. The current portfolio of the company includes Auryxia (ferric citrate), a medicine approved and marketed in the United States for the control of serum phosphorus levels in adult patients with dialysis-dependent chronic kidney disease and the treatment of iron deficiency anemia, in adult patients with non-dialysis-dependent chronic kidney disease, Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, inhibitor approved in Japan for the treatment of anemia due to chronic kidney disease, and HIF-PH inhibitors in preclinical development.

About RXST RxSight Inc.

RxSight Inc is a commercial-stage medical technology company dedicated to improving the vision of patients following cataract surgery. It offers intraocular lens technology that enables doctors to customize and optimize visual acuity for patients after cataract surgery. The company operates and manages its business in one reportable segment, the research and development, manufacture, and sale of light adjustable lenses and related capital equipment.

Share on Social Networks: